RESTORE®, CARDIONOVUM’s innovative paclitaxel-coated balloon for coronary applications has received market approval for China, making it the first drug-coated balloon (DCB) available in China to treat two indications: in-stent restenosis (ISR) and small vessel disease (SVD). The approval was given based on the impressive results from two solidly designed clinical studies in Chinese populations: RESTORE ISR CHINA and RESTORE SVD CHINA.
Cardionovum invites you to attend a scientific session:
GAP IN KNOWLEDGE: Role of drug-coated balloons in de novo lesions Dr Alfonso Ielasi - the PI of the Hyper study - will share his findings on the topic of: Clinical scenario: “A patient treated with a hybrid DES-DEB strategy”
Thursday 11st October at 14:30h ROOM AMBER 5-6
Allianz MiCo - Milano Congressi South Wing Viale Eginardo - Gate 2 20149 Milano, Italy
You are welcome to visit us at booth #45, 2nd Floor (ALA SUD)
Cardionovum invites you to participate in on demand interviwes:
XLIMIT Trial RCT, with Dr. Luca Testa from Italy. Goal: to assess angiographic and clinical performance of the Xlimus Biodegradable Polymer Sirolumus-eluting stent versus a gold standard like Synergy Biodegradable Polymer Everolimus Stent in patients treated with percutaneous coronary angioplasty.
Hyper Registry with Dr. Alfonso Ileasi from Italy. Goal: Asses the clinical results after a Hybrid Approach in diffuse CAD lesions longer tan 28mm combinig Restore DCB and New generation DES.